Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay
✍ Scribed by Antoinette Y. N. Schouten-van Meeteren; Paul van der Valk; Hans C. van der Linden; Annette C. Moll; Saskia M. Imhof; Dieuwke R. Huismans; Anne H. Loonen; Anjo J. P. Veerman
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 112 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
Retinoblastoma is frequently treated with chemotherapy to facilitate intraocular therapy, as well as to diminish or delay radiotherapy in invasive disease. It is also used more extensively in patients with dissemination to the central nervous system and/or the bone marrow. Once the disease has spread, the prognosis is poor. Radiotherapy is effective in ocular retinoblastoma, but is associated with facial deformation and a higher chance for second primary tumors in the irradiation field. These sequelae emphasize the need to determine more effective chemotherapy schedules and local treatment. The aim of this study is to investigate the relation between in vitro drug resistance for ten cytostatic drugs and histopathologic features in primary retinoblastoma.
MATERIALS AND METHODS.
Forty-four fresh samples of primary retinoblastoma were tested for in vitro drug resistance using the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. The histopathologic features for differentiation, invasion and intra-ocular extension, necrosis, mitosis, and apoptosis were scored.